authors
- Hay, Annette E
- Murugesan, Alli
- DiPasquale, Ashley M
- Kouroukis, Tom
- Sandhu, Irwindeep
- Kukreti, Vishal
- Bahlis, Nizar J
- Lategan, Johan
- Reece, Donna E
- Lyons, John F
- Sederias, Joana
- Xu, Hao
- Powers, Jean
- Seymour, Lesley K
- Reiman, Tony
A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- June 2, 2016
has subject area
- 1103 Clinical Sciences (FoR)
- Aurora Kinases (MeSH)
- Benzimidazoles (MeSH)
- Drug Resistance, Neoplasm (MeSH)
- Humans (MeSH)
- Immunology (Science Metrix)
- Multiple Myeloma (MeSH)
- Protein Kinase Inhibitors (MeSH)
- Recurrence (MeSH)
- Treatment Failure (MeSH)
- Treatment Outcome (MeSH)
- Urea (MeSH)
published in
- Leukemia and Lymphoma Journal